362 completed, 134 active not recruiting, 117 terminated, 107 recruiting. 494 Phase 2, 334 Phase 1, 79 Phase 3, 11 Early Phase 1, 7 Not applicable.
Follow Ipilimumab: new trials by email Literature Review of Ipilimumab trials Research Report on Ipilimumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. Nivolumab & Ipilimumab, Nivolumab + Ipilimumab - Advanced Kidney Cancer | Phase 3 | Not yet recruiting | Guliz Ozgun | 142 | 2027-02-01 | 2026-10-01 |
| A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy - Non-Small Cell Lung Cancer, Metastatic Lung Cancer | Phase 2 | Recruiting | University of Chicago | 39 | 2026-12-12 | 2026-06-16 |
| iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma iSCIB1+, Nivolumab & Ipilimumab, Placebo - Melanoma (Skin Cancer), Advanced Melanoma | Phase 3 | Not yet recruiting | Scancell Ltd | 550 | 2026-12-01 | 2026-09-11 |
| Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab (anti-CTLA4) - Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer | Phase 1 | Not yet recruiting | Centre Georges Francois Leclerc | 77 | 2026-11-01 | 2026-05-14 |
| Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older Anakinra, Biospecimen Collection, Computed Tomography - Melanoma | Phase 1 | Not yet recruiting | University of Southern California | 40 | 2026-11-01 | 2026-09-24 |
| A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer Ivonescimab (dose level 1) combined with Cadonilimab, Ivonescimab (dose level 2) combined with Cadonilimab, Ivonescimab combined with Ipilimumab - Renal Cell Carcinoma, Clear Cell | Phase 2 | Not yet recruiting | Summit Therapeutics | 100 | 2026-10-19 | 2026-10-16 |
| A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab - Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 27 | 2026-10-01 | 2026-10-05 |
| Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial Ipilimumab & Sintilimab, Sintilimab - Locally Advanced Rectal Cancer (LARC) | Phase 2 / Phase 3 | Not yet recruiting | Yao Hongwei | 120 | 2026-10-01 | 2026-10-19 |
| Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma Ipilimumab, Nivolumab - Melanoma | Phase 2 | Withdrawn | University of Utah | 2026-10-01 | 2026-10-19 | |
| Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial Ipilimumab & Sintilimab, Sintilimab - Locally Advanced Rectal Cancer (LARC) | Phase 2 / Phase 3 | Not yet recruiting | Yao Hongwei | 120 | 2026-10-01 | 2026-10-19 |
| Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) Stereotactic Body Radiation Therapy (SBRT), Pembrolizumab, Nivolumab - Head and Neck Cancer, Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Mark Bernard | 35 | 2026-09-09 | 2026-10-14 |
| Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy BreakVax, Ipilimumab 2.5 mg, Pembrolizumab - Glioblastoma (GBM) | Phase 1 / Phase 2 | Not yet recruiting | BreakBio Corp | 10 | 2026-09-01 | 2026-08-19 |
| Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study Sintilimab, ipilimumab, Radscopal Radiotherapy - Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 28 | 2026-09-01 | 2026-08-10 |
| PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma Cemiplimab, Lpilimumab, Fianlimab - Melanoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2026-09-01 | 2026-04-06 |
| Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy BreakVax, Ipilimumab 2.5 mg, Pembrolizumab - Triple-Negative Breast Cancer (TNBC) | Phase 1 / Phase 2 | Not yet recruiting | BreakBio Corp | 10 | 2026-09-01 | 2026-08-19 |
| Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases Bevacizumab, Ipilimumab, Nivolumab - Melanoma Brain Metastases | Phase 1 / Phase 2 | Recruiting | Melanoma and Skin Cancer Trials Limited | 46 | 2026-08-31 | 2026-10-13 |
| Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma Nivolumab, Ipilimumab (3 mg/kg) - Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 60 | 2026-08-21 | 2026-08-25 |
| NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma Pembrolizumab, Ipilimumab plus nivolumab - Melanoma (Skin Cancer), Melanoma Stage Stage IIIB | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 55 | 2026-08-06 | 2026-09-30 |
| Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer Ipilimumab (1mg/kg), Sinitilimab, Nab-paclitaxel + Cisplatin - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Recruiting | Sun Yat-sen University | 51 | 2026-08-01 | 2026-08-07 |
| Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial Ipilimumab Injection, Sintilimab injection, Lenvatinib - Renal Cell Carcinoma (Kidney Cancer), Immunotherapy | Phase 2 | Not yet recruiting | West China Hospital | 66 | 2026-08-01 | 2026-07-20 |
Showing 20 of 827. Sign in to see all of them.
Melanoma (253) · Carcinoma, Non-Small-Cell Lung (87) · Carcinoma, Renal Cell (64) · Neoplasm Metastasis (54) · Neoplasms (51) · Prostatic Neoplasms (35) · Lung Neoplasms (32) · Uveal Melanoma (29) · Pancreatic Neoplasms (28) · Carcinoma, Hepatocellular (27) · Brain Neoplasms (24) · Colorectal Neoplasms (24) · Sarcoma (22) · Breast Neoplasms (20) · Kidney Neoplasms (19)
Bristol-Myers Squibb (141) · National Cancer Institute (NCI) (65) · M.D. Anderson Cancer Center (49) · H. Lee Moffitt Cancer Center and Research Institute (17) · Memorial Sloan Kettering Cancer Center (17) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (17) · The Netherlands Cancer Institute (16) · Dana-Farber Cancer Institute (15) · NYU Langone Health (8) · Emory University (7) · Gustave Roussy, Cancer Campus, Grand Paris (7) · Abramson Cancer Center at Penn Medicine (6) · Massachusetts General Hospital (6) · Washington University School of Medicine (6) · AIO-Studien-gGmbH (5)
United States (592) · France (120) · Spain (104) · Canada (99) · Germany (98) · Italy (97) · Australia (88) · United Kingdom (83) · Netherlands (72) · Poland (65) · Belgium (62) · China (46) · Switzerland (43) · Japan (41) · Denmark (38)
Steven A. Rosenberg, MD, PhD (5) · Eric Jonasch, MD (3) · Frank S Hodi (3) · John E. Janik, MD (3) · Lawrence Fong, MD (3) · Michael Postow, MD (3) · Sumanta K Pal (3) · A P Chen (2) · Ahmad Tarhini (2) · Ahmad Tarhini, MD, PhD (2)
PMID 25667295, PMID 36648215, PMID 24695685, PMID 25649350, PMID 39504507, PMID 35383907, PMID 42836590, PMID 21917607, PMID 24577748, PMID 24844912, PMID 25891173, PMID 29489427, PMID 32376721, PMID 32691060, PMID 33001135, PMID 33058158, PMID 33362722, PMID 33558721, PMID 33735809, PMID 34503735, PMID 34663559, PMID 34855329, PMID 35031545, PMID 36450385, PMID 36989829, PMID 37146227, PMID 37328287, PMID 39369790, PMID 39378385, PMID 39437804, PMID 40614118, PMID 42579028, PMID 12826605, PMID 16087944, PMID 16283570, PMID 16882708, PMID 18523152, PMID 18974373, PMID 19139884, PMID 19156911, PMID 20004617, PMID 20082117, PMID 20525992, PMID 20842054, PMID 21106722, PMID 21639810, PMID 21911310, PMID 22123319, PMID 22326922, PMID 22456429
2016 (23), 2017 (19), 2018 (19), U10CA180820 (11), 2023 (10), U10CA180821 (10), 2014 (8), 2015 (7), 2025 (7), U10CA180868 (7), U10CA180888 (7), UM1CA186691 (6), 2019 (5), P30CA033572 (5), P30CA138292 (5)